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Having determined the complete amino acid sequence of a cytosolic phosphatase purified from bovine liver, we studied the role of this enzyme 
(referred to as 'PTPase') in the control of cell proliferation. We used NIH/3T3 fibroblasts, both normal and transformed by the oncogenes v-erbB, 
v-src, and v-raf: a synthetic gene coding for PTPase was transfected into, and overexpressed in, normal and transformed NIH/3T3 cells with resulting 
inhibition of cell growth. Inhibition of proliferation correlated with the level of foreign PTPase; growth in soft agar was also inhibited in 
transformants overexpressing the enzyme. However, PTPase overexpression did not inhibit the rapid turnover of inositol lipids stimulated by 
platelet-derived growth factor. We conclude that this novel PTPase is active on cell type-specific signalling substrates that control normal and 
transformed fibroblast proliferation. 
Phosphatase; Oncogene; Neoplasia; Inositol lipid 
1. INTRODUCTION 
Several growth factor receptors and oncoproteins 
have tyrosine kinase domains, and activation of tyro- 
sine kinases is a necessary pre-requisite for the stimula- 
tion of cell growth. The phosphorylated state of any 
given protein is the result of a finely regulated balance 
of kinase and phosphatase activities, and phosphoty- 
rosine protein phosphatases have been proposed as key 
regulators of cell proliferation [1]. A recent study indi- 
cated that expression of rat PTP1 phosphatase in mouse 
3T3 fibroblasts transformed by the v-src oncogene, neg- 
atively affected some transformed features of these cells 
[2]. Rat PTP1 is an ubiquitous, single domain, phos- 
phatase associated with cell membranes. 
We determined the complete primary structure of a 
different cytosolic phosphatase purified from bovine 
liver (originally termed low Mr acid phosphatase; in this 
study defined as 'PTPase') [3]. The reaction mechanism 
of this enzyme involves the formation of a cysteinyl- 
phosphate intermediate [4] which is peculiar of enzymes 
of the PTPase family [5,6]. Furthermore, this low Mr 
PTPase shows in its active site the signature motif (se- 
quence: XCXXXXXRXX) which is a main feature of 
all the members of this family [5]. With site-directed 
mutagenesis [7], and with kinetic studies [3], we demon- 
strated that C and R residues are both essential for the 
enzyme catalytic mechanism. The enzyme actively 
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dephosphorylated phosphotyrosine-containing proteins 
without affecting phosphoserine or phosphothreonine 
[8,9]. We also demonstrated that PTPase dephosphor- 
ylated the tyrosine-autophosphorylated epidermal 
growth factor receptor in vitro [8], and inhibited the 
growth of v-erbB-transformed NIH/3T3 cells [10]. In 
order to ascertain whether the inhibitory effect of 
PTPase was directly associated with growth factor re- 
ceptor tyrosine phosphorylation, we decided to extend 
our study to cells transformed by the v-src and v-raf 
oncogenes. In fact, these oncogenes code for non-recep- 
torial transforming proteins having distinct functions 
both within (src), and outside (raf) the tyrosine kinase 
signalling cascade; v-src encodes a membrane-associ- 
ated non-receptor tyrosine kinases which is constitu- 
tively active; v-rafcodes for a cytosolic serine/threonine 
kinase significantly homologous to protein kinase C 
(for review see [11]). 
2. MATERIALS AND METHODS 
2.1. Determination of PTPase level 
PTPase determination was carried out by a non-competitive sand- 
wich ELISA. Antisera to the enzyme purified from bovine liver were 
raised in rabbits. From mixture of equal volumes of three rabbit 
antisera, specific antibodies were purified by affinity chromatography 
using the antigen linked to Sepharose 4B as immunoadsorbent. Anti- 
bodies were then conjugated to horseradish peroxidase [l 2]. Microtitre 
polystirene wells were coated with affinity-purified antibodies. After 
washing cycles, standards and samples, diluted in the assay buffer 
(TBS-T), were added to the wells, and incubated overnight at 4°C. 
After washing, the appropriate dilution of conjugate was added to 
each well for three hours. The quantity of formed immunocomplex 
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was then determined by measuring the peroxidase activity using o- 
phenylendiamine as substrate. Standard solutions of PTPase purified 
from rat [13] and bovine liver were used to assess the basal evel of the 
native enzyme and its overexpression. The lower limit of quantitation 
was 0.1 ng/ml for overexpressed PTPase, and 0.75 ng/ml for the native 
one, with linear ranges of 0.1 to 2 ng/ml, and 0.75 to 20 ng/ml, 
respectively. Lysates of different cell lines, depleted of PTPase by 
repeated incubation in the presence of antibodies linked to Sepharose- 
4B and supplemented with the enzyme standards, howed linear and 
reproducible concentration/absorbance relationship. The responsive- 
ness of lysates, as treated above, were very similar to the assay buffer 
supplemented with the same PTPase standards. In the used range there 
were negligible ffects of lysate dilutions on the assays. Quantitative 
values determined by ELISA were consistent with the increase of 
hydrolytic activity assayed in selected clone lysates using p-nitrophen- 
ylphosphate as substrate. 
2.2. TransJ~wtion and overexpression of the synthetic PTPase gene 
In order to study the effect of PTPase overexpression cell behav- 
iour, a synthetic gene coding for the bovine isoform of the enzyme was 
transfected into normal and oncogene-transformed NIH/3T3 fibro- 
blasts (obtained from the Laboratory of Cellular and Molecular Biol- 
ogy of the National Cancer Institute, NIH, Bethesda, USA). The same 
cell lines were also transfected with a gene coding only for resistance 
to neomycin in order to obtain clones that had undergone the same 
treatment but were not overexpressing the PTPase. Restriction endo- 
nucleases, E. coli DNA polymerase I (Klenow fragment), and DNA 
ligase were obtained from Promega nd used under standard condi- 
tions. DNA sequence analysis was carried out using the UBS-Se- 
quenase kit. Neomycin (G418) was from Sigma Chem. Co. Plasmid 
preparation was as follows, pSVPTP: pExPAIII [14] was cut with 
HindIII, treated with Klenow polymerase, and then partially digested 
with NcoI to obtain the 477 bp DNA fragment coding for PTPase; this 
band was cloned in pGEM5Zf(+) vector (Promega) cut with SalI, 
treated with Klenow polymerase and cut with NcoI in order to obtain 
the pGEMPTP construct. The SphI HindIII band obtained from 
pGEMPTP, containing the synthetic DNA, was cloned in the blunt- 
ended EcoRI site of the pSVT7 vector [15] in order to obtain the 
pSVPTP plasmid. DNA sequence analysis confirmed that the expected 
sequence (containing an ATG start codon followed by the coding 
sequence for PTPase and a TGA stop codon) had been inserted in the 
right orientation downstream of the SV40 early promoter of the 
pSVT7 plasmid. Transfection experiments were performed as follows; 
10/lg of pSVPTP and 0.5/lg of pK0neo (i.e. the function coding for 
resistance to neomycin, used to select transfection-positive clones, 
and, when transfected alone, as a control) were used with the calcium 
phosphate coprecipitation technique [16-18] for transfecting 1.5 mil- 
lion cells on a 100-ram plate. Selection of stable neomycin (G-418)- 
resistant clones was performed supplementing the medium with 
500 ,ug/ml of antibiotic, mRNA analysis was performed using the [32p]_ 
labelled PTPase synthetic DNA as a probe, in high stringency condi- 
tions (2 x SET at 65°C). Total RNA preparation and Northern blot 
analysis were performed according to Solito et al. [19]. Both normal 
and transformed cells were also transfected with pK0neo alone. Stable 
overexpression f PTPase was assessed by ELISA, and the level of the 
enzyme remained approximately the same for up to two months. 
2.3. Determination of thymidine incorporation and growth kinetics 
Normal NIH/3T3 v-erbB, v-src, and v-raftransformants have been 
previously described [20,21]. The kinetics of growth, and the incorpo- 
ration of [3H]thymidine (from New England Nuclear) were performed 
as previously described [21,22]. Data obtained measuring [3H]thymid- 
ine incorporation were normalized for the number of cells per dish. 
2.4. Determination of inositol lipid metabolism 
Cells prelabelled to equilibrium with [3H]myo-inositol (New Eng- 
land Nuclear) were stimulated with 100 ng/ml of platelet-derived 
growth factor, BB chain homodimer (PDGF-BB) (Pepro Tech Inc.) 
in the presence of 20 mM LiC1 as described [21,22]. In some experi- 
ments, tyrphostin (Calbiochem; 100/IM) was added 6 h before stimu- 
lation with PDGF-BB. In a first series of experiments, calcium-mobi- 
lizing inositol (l,4,5)-trisphosphate was separed by high-pressure liq- 
uid chromatography; as expected from previously published results, 
the compound was rapidly formed and degraded, reaching its peak 
about 30 s after stimulation with PDGF-BB both in normal cells and 
in transfectants. Thus, we decided to routinely measure the formation 
of total inositol polyphosphates which were extracted and separated 
by ion-exchange chromatography (with Dowex resin from Bio-Rad) 
as described [22]. 
3. RESULTS AND DISCUSSION 
We determined the effect of PTPase overexpression 
on DNA synthesis in normal and transformed NIH/3T3 
fibroblasts which had been serum-starved for 24 h. Fig. 
1A shows that cells overexpressing the PTPase gene 
incorporated about half as much [3H]thymidine as their 
untransfected counterpart. We also monitored trans- 
formed cell division by following growth kinetics over 
extended periods of time in the presence of complete 
culture medium (serum-containing Dulbecco's modified 
Eagle medium (DMEM). Fig. 1B shows that PTPase 
overexpression significantly inhibited cell proliferation 
under these conditions, thus demonstrating that inhibi- 
tion of growth was independent of culture conditions. 
To determine whether inhibition of proliferation was 
related to the level of PTPase expression, we performed 
the same experiment described in Fig. 1, using different 
transfected clones overexpressing PTPase at different 
levels. Fig. 2 shows a correlation between PTPase ex- 
pression and inhibition of cell proliferation in v-src (A) 
and v-raf(B) transformants. Although inhibition of cell 
growth correlated with PTPase levels, it was not linearly 
proportional to the level of PTPase overexpression. We 
also could not establish a 'threshold' of PTPase that 
invariably inhibited cell proliferation to the same extent. 
Identical results were obtained in v-erbB transformants, 
and in normal NIH/3T3 cells overexpressing the 
PTPase gene (data not shown). Normal cells required 
lower expression of the PTPase to be growth-inhibited; 
these results suggest hat PTPase inhibited with more 
efficiency normal cells that were growing at a lower rate 
if compared with transformants. This might be reason 
why we could not select normally growing clones har- 
boring higher level of PTPase, just because they would 
not be able to proliferate. 
The effect of PTPase overexpression another assay 
of transformation, growth in semi-solid medium, was 
studied in oncogene-transformed cells that were capable 
of forming colonies in soft agar. Fig. 3 shows that 
PTPase-overexpressing transformants formed a signifi- 
cantly reduced number of colonies as compared with 
their untransfected counterpart. These results indicate 
that PTPase exert multifaceted effects on different para- 
meters of transformation. However, PTPase-overex- 
pressing cells did not show appreciable changes of their 
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t rans formed phenotype,  as mon i to red  by l ight micro-  
scope observat ion.  
PTPase  inhib i t ion o f  cell pro l i ferat ion dr iven by on- 
cogenes whose products  differed greatly in structure 
and funct ion,  suggested that  PTPase  did not  direct ly 
interact  with t rans forming  proteins,  but  rather  inhibi ted 
downst ream signal l ing pathways.  In an a t tempt  to de- 
termine whether  a known second messenger  system was 
affected by PTPase  expression, we studied the metabo-  
l ism of  inositol  l ipids [23] induced by PDGB-BB and/or  
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Fig. 1. Thymidine incorporation and growth kinetics of normal and 
transformed cells overexpressing the synthetic gene for PTPase. The 
kinetics of growth, and the incorporation of [3H]thymidine were per- 
formed as described. Data obtained measuring [3H]thymidine incorpo- 
ration were normalized for the number of cells per dish. (A) Wild-type 
(or pK0neo-transfected) normal and transformed NIH/3T3 cells, and 
cells overexpressing the PTPase gene were serum-starved for 24 h, 
after which [3H]thymidine incorporation was measured by pulse (4 h) 
labelling. Results are expressed as % of incorporated [3H]thymidine 
before starvation (i.e. thymidine incorporation of growing cells was 
taken as 100%), and are means + S.E. of quadruplicate samples from 
one experiment, representative of three others that gave qualitatively 
identical results. (B) Wild-type (or pK0neo-transfected) transfor- 
mants, and transformants overexpressing the PTPase gene were plated 
at the same density. Cell number was determined every 24 h for 3 days 
thereafter. Data from one representative experiment are reported as 
means + S.E. (n = 8). 
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Fig. 2. Growth kinetics in transformed ceils expressing different levels 
of PTPase. Clones of v-src (panel A), and v-raf  (panel B) transfor- 
mants expressing different levels of PTPase were assayed as described, 
and [3H]thymidine incorporation was determined every 24 h after 
plating. On the side of the Figure is reported the relative fold increase 
of PTPase in each clone (C1 number). The level of PTPase in untrans- 
fected (or pK0neo-transfected) cells was normalized as l, and the 
PTPase value referring to each clone indicates how many fold was the 
PTPase level increased above normal cells. Data from one representa- 
tive experiment are reported as means + S.E. (n = 8). 
serum in normal  and t rans formed f ibroblasts harbor ing  
the PTPase  gene. As  expected,  PTPase-N IH/3T3  f ibro- 
blasts showed impai red mi togen ic  response to PDGB-  
BB. Inh ib i t ion  o f  PDGF-BB- induced  [3H]thymidine in- 
corporat ion  in PTPase- t ransfected cells was about  50% 
(N IH/3T3  st imulated with 100 ng/ml  o f  PDGF-BB:  
38,530 + 1267. PTPase-N IH/3T3:19 ,852  + 859, cpm 
_+ S.E. The exper iment  was per fo rmed in cells that  had 
been serum-starved for 24 h, and then st imulated with 
PDGF-BB for 24 h). However ,  when we measured  inos- 
itol l ipid turnover  we found that  inositol  phosphate  
fo rmat ion  in response to PDGF-BB in PTPase- t rans-  
fected cells was a lmost  identical  to that o f  untransfected 
cells (Fig. 4). Tyrphost in ,  a known inh ib i tor  o f  tyrosine 
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kinases [24], reduced inositol phosphate format ion in 
response to PDGF-BB both in normal  and PTPase- 
transfected cells. The inhibitory effect of  tyrphost in was 
unaffected by PTPase overexpression. Qual itat ively 
identical results (i.e. no effect of  PTPase overexpression 
on inositol l ipid metabol ism) were obtained when v- 
erbB, v-src, and v-raf transformants overexpressing the 
PTPase gene were st imulated with serum (data not 
shown). 
Recently, attent ion has focused on tyrosine phos- 
phatases as putat ive counterregulators of  mitogenic ty- 
rosine kinases. Receptor- l ike and membrane-assoc iated 
phosphatases with src homology (SH2) domains and 
PEST (prol ine-glutamic acid/serine/threonine) se- 
quences have been characterized, thus leading to sug- 
gestion that phosphatase activity might be regulated in 
a manner  similar to that of  tyrosine kinases (for re- 
view see [1]). The PTPase we described in this study is 
pecul iar among other enzymes of  its class in that, with 
the exception of  the active site, it does not share general 
sequence homology with other known phosphatases,  
neither does it contain SH2 domains or PEST sequences 
[3]. Our results demonstrate that PTPase expression was 
inversely related to cell prol i ferat ion, either in normal  
or oncogene-transformed fibroblasts. The effect of  
PTPase overexpression on cells t ransformed by the raf 
oncogene (i.e. by a non tyrosine kinase-encoding onco- 
gene), together with the lack of  effect on inositol l ipid 
metabol ism, suggested that PTPase acts on downstream 
phosphory lated substrates that are activated by growth 
factor-dependent mitogenic st imulat ion as well as by 
oncogenic transformation.  PTPase inhibit ion of  cell 
prol i ferat ion in a rather nonspecific manner  led us to 
suspect hat PTPase overexpression was causing some 
type of  damage to cell structure or was acting 'pharma-  
soft agar growth, N. o f  co lon ies  
[3H] inos i to l  phosphates,  cpm 
cont tp PDGF tp+PDGF 
treatment 
Fig. 4. Inositol lipid metabolism inPTPase-overexpressing f broblasts. 
Cells prelabelled to equilibrium with [3H]myo-inositol were stimulated 
with 100 ng/ml of PDGF-BB for 1 h. In some experiments, yrphostin 
(100/~M) was added 6 h before stimulation with PDGF-BB. Total 
inositol phosphates were extracted and separated by ion-exchange 
chromatography. Data from one representative experiment are re- 
ported as means + S.E. (n = 3). 
cologically'.  However, PTPase overexpression did not 
affect the prol i ferat ion of  either normal  [25] or v-erbB- 
t ransformed [26,27] 32D hematopoiet ic  ells (not 
shown), thus suggesting that the inhibitory effect ob- 
served in NIH/3T3 f ibroblasts was not due to nonspe- 
cific cell damage. Thus, comparat ive study of  protein 
substrates dephosphory lated by PTPase may help to 
identify the critical regulators of  cell prol i ferat ion in 
response to normal  and aberrant  growth stimuli. 
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Fig. 3. Soft agar growth of v-erbB, v-src, and v-raf transformants 
overexpressing the synthetic gene for PTPase. Plates were previously 
coated with 1.2% sea plaque agarose medium, in order to prevent cell 
adhesion. Single cell suspensions (2000 cells/ml) were plated in 0.27% 
agarose medium plus 10% calf serum. Visible colonies were scored at 
14 days. The results represent the mean values of three independent 
experiments. 
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